Covid19-Sources

Einige Menschen tragen das Coronavirus über einen langen Zeitraum in sich, wie Studien aus Großbritannien und den USA belegen

Wer mit dem Coronavirus erkrankt ist, muss weiter Vergütung erhalten. Selbst dann, wenn die Krankheit symptomlos verläuft. Die Richter am Bundesarbeitsgericht entschieden den Fall eines Produktionsarbeiters.

Recent research shows that bivalent mRNA COVID vaccines do not increase stroke risk, a claim previously unverified large-scale studies.

The coronavirus disease 2019 (COVID-19) pandemic has caused significant medical, social, and economic impacts globally, both in the short and long term. Although most individuals recover within a few days or weeks from an acute infection, some experience longer lasting effects. Data regarding the postacute sequelae of severe acute respiratory...

In children aged 5–11 years, mRNA vaccines are moderately effective against infections with the omicron variant, but are likely to protect well against COVID-19 hospitalisations. Vaccines were reactogenic but probably safe. Findings of this systematic review can serve as a basis for public health policy and individual decision making on COVID-19 vaccination in children aged 5–11 years.

This cohort study analyzes data from 3 commercial claims databases to conduct near–real-time monitoring of health outcomes following BNT162b2 COVID-19 vaccination in the US pediatric population aged 5 to 17 years.

OBJECTIVES:. Vaccination reduces the risk of acute coronavirus disease 2019 (COVID-19) in children, but it is less clear whether it protects against long COVID. We estimated vaccine effectiveness (VE) against long COVID in children aged 5 to 17 years.METHODS:. This retrospective cohort study used data from 17 health systems in...

This study uses data from 3 prospective cohort studies conducted in the US to assess vaccine effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 infection and symptomatic COVID-19 among children and adolescents.

Background: The efficacy of the BNT162b2 vaccine in pediatrics was assessed by randomized trials before the Omicron variant’s emergence. The long-term durability of vaccine protection in this population during the Omicron period remains limited. Objective: To assess the effectiveness of BNT162b2 in preventing infection and severe diseases with various strains of the SARS-CoV-2 virus in previously uninfected children and adolescents. Design: Comparative effectiveness research accounting for underreported vaccination in 3 study cohorts: adolescents (12 to 20 years) during the Delta phase and children (5 to 11 years) and adolescents (12 to 20 years) during the Omicron phase. Setting: A national collaboration of pediatric health systems (PEDSnet). Participants: 77 392 adolescents (45 007 vaccinated) during the Delta phase and 111 539 children (50 398 vaccinated) and 56 080 adolescents (21 180 vaccinated) during the Omicron phase. Intervention: First dose of the BNT162b2 vaccine versus no receipt of COVID-19 vaccine. Measurements: Outcomes of interest include documented infection, COVID-19 illness severity, admission to an intensive care unit (ICU), and cardiac complications. The effectiveness was reported as (1-relative risk)*100, with confounders balanced via propensity score stratification. Results: During the Delta period, the estimated effectiveness of the BNT162b2 vaccine was 98.4% (95% CI, 98.1% to 98.7%) against documented infection among adolescents, with no statistically significant waning after receipt of the first dose. An analysis of cardiac complications did not suggest a statistically significant difference between vaccinated and unvaccinated groups. During the Omicron period, the effectiveness against documented infection among children was estimated to be 74.3% (CI, 72.2% to 76.2%). Higher levels of effectiveness were seen against moderate or severe COVID-19 (75.5% [CI, 69.0% to 81.0%]) and ICU admission with COVID-19 (84.9% [CI, 64.8% to 93.5%]). Among adolescents, the effectiveness against documented Omicron infection was 85.5% (CI, 83.8% to 87.1%), with 84.8% (CI, 77.3% to 89.9%) against moderate or severe COVID-19, and 91.5% (CI, 69.5% to 97.6%) against ICU admission with COVID-19. The effectiveness of the BNT162b2 vaccine against the Omicron variant declined 4 months after the first dose and then stabilized. The analysis showed a lower risk for cardiac complications in the vaccinated group during the Omicron variant period. Limitation: Observational study design and potentially undocumented infection. Conclusion: This study suggests that BNT162b2 was effective for various COVID-19–related outcomes in children and adolescents during the Delta and Omicron periods, and there is some evidence of waning effectiveness over time. Primary Funding Source: National Institutes of Health.

About 6 million children in the US might be living with post–COVID-19 condition, also known as long COVID. A recent narrative review in Pediatrics parsed the existing research from the past 3 years about how long COVID presents in children and what the risk factors are for developing the condition.

Nature - Evaluation of evidence generated to test 19 proposed policy recommendations and guidance for the future.

Long COVID is a thorn in the side of "back to normal." Attempts to silence patients are intensifying.

New research indicates that antibiotics can effectively target bacteria in the gut that harbor the virus that causes COVID-19 and produce toxin-like peptides that contribute to COVID-19-related symptoms.

Silver Spring/Maryland – Der Verdacht, dass die Impfung mit dem bivalenten Booster des mRNA-Impfstoffs von Biontech/Pfizer einen Schlaganfall auslösen kann, hat...

MRI scans of long COVID patients with brain fog suggest that the blood brain barrier may be leaky.

Waves of COVID-19 infections have continued all around the world as new variants appear. The expectation that previous infections would reduce the probability or severity of the disease has proved to be incorrect [1]. While deaths during the acute phase have been decreasing, in part due to improved disease treatment and vaccination, excess mortality continues … Continued

A recent study estimates millions of children are suffering from long COVID. Michael George has more on why we still know so little about the illness and one mother's search for answers.

A message to "claim your dose by making a vaccination appointment" improved vaccine coverage by 2 percentage points.

DMZ – LEBEN ¦ Sarah Koller ¦ Inmitten der weltweiten Krise der COVID-19-Pandemie gibt es Geschichten, die oft übersehen werden - Geschichten von Familien, die im Schatten dieser turbulenten Zeit kämpfen. Eine solche Familie ist auch die von Frau Müller*, einer Krebspatientin im metastasierten Stadium seit 2018. Als die Pandemie begann, befanden sich ihre Kinder noch in der Schulpflicht, ihr Sohn stand mitten im Abitur. Frau Müller hatte bereits im Vorfeld mit Radiologen, Onkologen und Thoraxchirurgen über ihr erhöhtes Risiko einer COVID-19-Infektion gesprochen. Doch als sie sich vor Ort erkundigte, wurde ihr eine entmutigende Realität offenbart. Man sagte ihr, dass sie bei einer Infektion wahrscheinlich sterben würde, aber sie wurde ermutigt, die Gefahr herunterzuspielen, um ihrem Sohn nicht zusätzlich Sorgen zu bereiten. Ihnen wurde der "häusliche Infektionsschutz" empfohlen: keine persönlichen Treffen, ständiges Tragen von Masken für Frau Müller im Haus, getrennte Nutzung von Küche und Bad und keine gemeinsamen Mahlzeiten. Trotz ihrer Bemühungen, die Situation zu normalisieren, spürte ihr Sohn den Vertrauensverlust zutiefst. Er fühlte sich wie ein Mittel zum Zweck für die Wirtschaft, anstatt als geliebtes Familienmitglied wahrgenommen zu werden. Die Entscheidung, ob er im Distanzunterricht bleiben durfte, lag nicht bei den Eltern, sondern beim Schulamt. Nach zahlreichen Anstrengungen und Tränen wurde schließlich zugestimmt, dass er bis zur Impfung im Fernunterricht bleiben durfte. Doch auch dort stieß die Familie auf Herausforderungen. Die Schule war unzureichend auf den digitalen Unterricht vorbereitet, und einige Lehrer beschwerten sich über den zusätzlichen Aufwand, den Frau Müllers Sohn verursachte. Es gab grundsätzlich sehr wenige, motivierte Lehrkräfte. Als es dann endlich Zeit für die Impfung war, erlebte Frau Müller eine weitere Enttäuschung. Obwohl sie einen Termin für den Biontech-Impfstoff hatte, wurde ihr vor Ort mitgeteilt, dass an diesem Tag ausschließlich der AstraZeneca-Impfstoff verabreicht wurde. Trotz ärztlicher Empfehlungen, dass sie aufgrund von Nebenwirkungen nicht mit AstraZeneca geimpft werden sollte, wurde ihr keine andere Wahl gelassen. Der Umgang mit der Situation hinterließ bei Frau Müller und ihrer Familie einen bleibenden Eindruck. Sie wurden von der Politik im Stich gelassen und fühlten sich unverstanden und alleingelassen. Die Pandemie ist noch nicht vorbei und trotzdem fühlen sich vulnerable Personen wie Frau Müller immer noch verletzlich und im Stich gelassen. Sie werden wegen ihrer Vorsichtsmaßnahmen beschimpft und stigmatisiert. Ihr täglicher Kampf ums Überleben wird durch jede Einkaufsreise und jeden Arztbesuch zusätzlich erschwert. Frau Müller und ihre Familie sind nur eine von vielen "Schattenfamilien", die in dieser Pandemie unsichtbar bleiben. Ihre Geschichte zeigt die dringende Notwendigkeit auf, für diese Menschen einzustehen und sie zu unterstützen, während sie weiterhin um ihr Überleben kämpfen. Wir alle sollten uns bewusst sein, dass hinter den Statistiken und Schlagzeilen echte Menschen mit echten Geschichten stehen. Lassen Sie uns gemeinsam diese Menschen unterstützen und sicherstellen, dass sie die Unterstützung erhalten, die sie verdienen. (*Name geändert, um die Privatsphäre zu schützen)"

Experten schlagen Alarm: In Japan häufen sich die Fälle einer seltenen, aber gefährlichen bakteriellen Erkrankung. Innerhalb von nur zwei Monaten registrieren die Behörden fast 400 neue Infektionen. Die Ursache für den dramatischen Anstieg könnte mit der Corona-Pandemie zusammenhängen.

BackgroundAs about 10% of patients with COVID-19 present sequelae, it is important to better understand the physiopathology of so-called long COVID.MethodTo ...

In Japan wird seit Anfang des Jahres ein rasanter Anstieg von Infektionen mit einer seltenen Krankheit registriert. Die Ursachen dafür sind bislang unklar.

With an estimated 65 million individuals suffering from Long COVID, validated therapeutic strategies as well as non-invasive biomarkers are direly needed to guide clinical management. We used blood digital transcriptomics in search of viral persistence and Long COVID diagnostic biomarkers in a real-world, general practice-based setting with a long clinical follow-up. We demonstrate systemic SARS-CoV-2 persistence for more than 2 years after acute COVID-19 infection. A 2-gene biomarker, including FYN and SARS-CoV-2 antisense RNA, correctly classifies Long COVID with 93.8% sensitivity and 91.7% specificity. Specific immune transcripts and immunometabolism score correlate to systemic viral load and patient-reported anxiety/depression, providing mechanistic links as well as therapeutic targets to tackle Long COVID. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement FWO grant to JVW ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the Ethical committee of University Hospitals Leuven (UZ Leuven, Belgium), all patients and controls have provided written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors.

Scientific Reports - A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models

AXA1125 is an experimental drug developed by Axcella Health that "increased β-oxidation and improved bioenergetics in preclinical models". It was studied as a treatment for non-alcoholic fatty liver disease and long COVID,

Although treatment with AXA1125 did not improve the primary endpoint (τPCr-measure of mitochondrial respiration), when compared to placebo, there were significant improvements in fatigue-based symptoms among patients living with Long COVID following a four-week treatment period. Further multicentre studies are needed to validate our findings in a larger cohort of patients with fatigue-dominant Long COVID.

BA.2.86 is a recently emerged, highly mutated SARS-CoV-2 variant that spreads in many countries and threatens human health. This study shows that BA.2.86, unlike closely related variants, can enter lung cells with high efficiency and in a TMPRSS2-dependent fashion and is resistant against therapeutic antibodies.

PDF | Background: The present study investigates the influence of COVID-19 on mortality in the sixteen German federal states. To examine this issue, we... | Find, read and cite all the research you need on ResearchGate